Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Epidemiological Characteristics and Genotypic Features of Rotavirus and Norovirus in Jining City, 2021-2022.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • معلومة اضافية
    • المصدر:
      Publisher: MDPI Country of Publication: Switzerland NLM ID: 101509722 Publication Model: Electronic Cited Medium: Internet ISSN: 1999-4915 (Electronic) Linking ISSN: 19994915 NLM ISO Abbreviation: Viruses Subsets: MEDLINE
    • بيانات النشر:
      Original Publication: Basel, Switzerland : MDPI
    • الموضوع:
    • نبذة مختصرة :
      Diarrhea, often caused by viruses like rotavirus (RV) and norovirus (NV), is a global health concern. This study focuses on RV and NV in Jining City from 2021 to 2022. Between 2021 and 2022, a total of 1052 diarrhea samples were collected. Real-Time Quantitative Fluorescent Reverse Transcriptase-PCR was used to detect RV-A, NV GI, and NV GII. For RV-A-positive samples, VP7 and VP4 genes were sequenced for genotype analysis, followed by the construction of evolutionary trees. Likewise, for NV-GII-positive samples, VP1 and RdRp genes were sequenced for genotypic analysis, and evolutionary trees were subsequently constructed. Between 2021 and 2022, Jining City showed varying detection ratios: RV-A alone (excluding co-infection of RV-A and NV GII) at 7.03%, NV GI at 0.10%, NV GII alone (excluding co-infection of RV-A and NV GII) at 5.42%, and co-infection of RV-A and NV GII at 1.14%. The highest RV-A ratios were shown in children ≤1 year and 2-5 years. Jining, Jinxiang County, and Liangshan County had notably high RV-A ratios at 24.37% (excluding co-infection of RV-A and NV GII) and 18.33% (excluding co-infection of RV-A and NV GII), respectively. Jining, Qufu, and Weishan had no RV-A positives. Weishan showed the highest NV GII ratios at 35.48% (excluding co-infection of RV-A and NV GII). Genotype analysis showed that, in 2021, G9P[8] and G2P[4] were dominant at 94.44% and 5.56%, respectively. In 2022, G8P[8], G9P[8], and G1P[8] were prominent at 75.86%, 13.79%, and 10.35%, respectively. In 2021, GII.3[P12], GII.4[P16], and GII.4[P31] constituted 71.42%, 14.29%, and 14.29%, respectively. In 2022, GII.3[P12] and GII.4[P16] accounted for 55.00% and 45.00%, respectively. RV-A and NV showed varying patterns for different time frames, age groups, and regions within Jining. Genotypic shifts were also observed in prevalent RV-A and NV GII strains in Jining City from 2021 to 2022. Ongoing monitoring of RV-A and NV is recommended for effective prevention and control.
    • References:
      Lancet Infect Dis. 2018 Nov;18(11):1211-1228. (PMID: 30243583)
      Expert Rev Anti Infect Ther. 2010 Feb;8(2):205-17. (PMID: 20109050)
      Int J Mol Sci. 2023 Jul 29;24(15):. (PMID: 37569563)
      Vaccine. 2009 Dec 30;27 Suppl 6:G72-81. (PMID: 20006144)
      Open Forum Infect Dis. 2023 May 29;10(7):ofad295. (PMID: 37404954)
      Arch Virol. 2021 Sep;166(9):2479-2486. (PMID: 34218319)
      Pathogens. 2021 Apr 26;10(5):. (PMID: 33925924)
      J Med Virol. 2022 Aug;94(8):3840-3846. (PMID: 35441419)
      Int J Mol Sci. 2023 May 22;24(10):. (PMID: 37240438)
      BMC Infect Dis. 2022 Jun 28;22(1):579. (PMID: 35764948)
      BMC Genomics. 2024 Apr 17;25(1):378. (PMID: 38632523)
      Vaccines (Basel). 2022 Feb 23;10(3):. (PMID: 35334978)
      J Virol Methods. 2002 Feb;100(1-2):107-14. (PMID: 11742657)
      J Virol Methods. 2015 Oct;223:96-104. (PMID: 26231786)
      Rev Med Virol. 2018 Nov;28(6):e2003. (PMID: 30156344)
      Mar Life Sci Technol. 2022 Nov 28;4(4):429-451. (PMID: 37078082)
      PLoS One. 2018 Dec 28;13(12):e0209245. (PMID: 30592717)
      BMJ Glob Health. 2022 Sep;7(9):. (PMID: 36660904)
      Biologicals. 2006 Dec;34(4):265-72. (PMID: 16492399)
      J Clin Virol. 2008 Aug;42(4):368-73. (PMID: 18378188)
      Food Environ Virol. 2013 Mar;5(1):13-23. (PMID: 23412719)
      Gut Pathog. 2021 Dec 24;13(1):77. (PMID: 34952625)
      J Gen Virol. 2019 Oct;100(10):1393-1406. (PMID: 31483239)
      Bing Du Xue Bao. 2015 Mar;31(2):170-3. (PMID: 26164943)
      Viruses. 2022 Dec 16;14(12):. (PMID: 36560815)
      Front Immunol. 2023 Jan 26;14:1125246. (PMID: 36776881)
      Heliyon. 2023 Jul 25;9(8):e18236. (PMID: 37554825)
      J Epidemiol Glob Health. 2022 Sep;12(3):292-303. (PMID: 35857268)
      Virol Sin. 2023 Jun;38(3):351-362. (PMID: 37030436)
      Emerg Infect Dis. 2023 Sep;29(9):1837-1841. (PMID: 37610173)
      Front Pediatr. 2023 Jan 23;11:1056129. (PMID: 36756237)
      Trop Med Int Health. 2019 Dec;24(12):1427-1433. (PMID: 31627250)
      Int J Environ Res Public Health. 2018 Dec 12;15(12):. (PMID: 30545071)
      Virol Sin. 2023 Oct;38(5):671-679. (PMID: 37619918)
      Front Microbiol. 2022 Sep 16;13:997957. (PMID: 36187963)
      Sci Rep. 2019 Dec 27;9(1):20012. (PMID: 31882797)
      J Biomed Sci. 2020 May 21;27(1):66. (PMID: 32438911)
      Einstein (Sao Paulo). 2016 Apr-Jun;14(2):278-87. (PMID: 27462899)
      J Clin Microbiol. 2012 Mar;50(3):966-76. (PMID: 22189107)
    • Grant Information:
      2021YFC2302003 National Key Research and Development Program of China; 202112060725 Science and Technology Development Funds for Shandong Medical and Health; 2023YXNS130 Key Research and Development Funds for Jining Medical and Health
    • Contributed Indexing:
      Keywords: genotypes; norovirus; rotavirus; viral gastroenteritis
    • الرقم المعرف:
      0 (Capsid Proteins)
    • الموضوع:
      Date Created: 20240627 Date Completed: 20240627 Latest Revision: 20240629
    • الموضوع:
      20250114
    • الرقم المعرف:
      PMC11209223
    • الرقم المعرف:
      10.3390/v16060925
    • الرقم المعرف:
      38932216